Endo

Pharma

Novartis pays $245M to settle Exforge generic pay-for-delay suit

Novartis will pay $245 million in separate settlements to end an Exforge "pay-for-delay" antitrust lawsuit.
Angus Liu Jan 3, 2023 11:22am

Already in bankruptcy, Endo halts Qwo production, lays off 90

Dec 7, 2022 10:50am

Endo plays it straight with new Peyronie's disease tool

Oct 28, 2022 9:05am

Endo continues patient-first ad approach for Dupuytren's

Oct 7, 2022 3:51pm

Endo's patent claims against Eagle don't hold up, again

Aug 19, 2022 11:20am

Endo files for bankruptcy, signs $450M opioid settlement

Aug 17, 2022 2:20pm